PMID- 30489553
OWN - NLM
STAT- MEDLINE
DCOM- 20190311
LR  - 20190311
IS  - 2326-6929 (Electronic)
IS  - 0011-4162 (Linking)
VI  - 102
IP  - 4
DP  - 2018 Oct
TI  - Xanthogranulomatous reaction to trametinib for metastatic malignant melanoma.
PG  - 283-286
AB  - Trametinib, a mitogen-activated extracellular signal-regulated kinase (MEK) 
      inhibitor, has demonstrated great promise in treating metastatic melanoma 
      associated with BRAF V600E and V600K mutations; however, it also is highly 
      associated with cutaneous adverse events (AEs). As both BRAF and MEK inhibitors 
      become increasingly used to treat malignant melanoma, it is important to better 
      characterize these AEs so that we can manage them. Herein, we present a case of a 
      66-year-old man who developed erythematous scaly papules on the face and 
      bilateral upper extremities after beginning therapy with trametinib. The severity 
      of the reaction worsened on trametinib monotherapy compared to combination 
      therapy with a BRAF inhibitor. Biopsy revealed a xanthogranulomatous reaction.
FAU - Min, Michelle S
AU  - Min MS
AD  - Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New 
      York, USA.
FAU - Yao, Jonathan
AU  - Yao J
AD  - Schweiger Dermatology, New York, New York, USA.
FAU - Chee, Nicole
AU  - Chee N
AD  - New York University, New York, New York, USA.
FAU - Sapadin, Allen N
AU  - Sapadin AN
AD  - Department of Dermatology, Hackensack University Medical Center, New Jersey, USA.
FAU - Shim-Chang, Helen
AU  - Shim-Chang H
AD  - Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New 
      York, USA.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Cutis
JT  - Cutis
JID - 0006440
RN  - 0 (Aniline Compounds)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (MEK inhibitor I)
RN  - 0 (Pyridones)
RN  - 0 (Pyrimidinones)
RN  - 33E86K87QN (trametinib)
RN  - MP1U0D42PE (Acrylonitrile)
SB  - IM
MH  - Acrylonitrile/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
MH  - Aged
MH  - Aniline Compounds/administration & dosage/adverse effects/*therapeutic use
MH  - Antineoplastic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Diagnosis, Differential
MH  - Granuloma/chemically induced/*diagnosis
MH  - Humans
MH  - Male
MH  - Melanoma/drug therapy/secondary
MH  - Neoplasm Staging
MH  - Pyridones/administration & dosage/adverse effects/*therapeutic use
MH  - Pyrimidinones/administration & dosage/adverse effects/*therapeutic use
MH  - Skin Neoplasms/drug therapy/pathology
MH  - Xanthomatosis/chemically induced/*diagnosis
EDAT- 2018/11/30 06:00
MHDA- 2019/03/12 06:00
CRDT- 2018/11/30 06:00
PHST- 2018/11/30 06:00 [entrez]
PHST- 2018/11/30 06:00 [pubmed]
PHST- 2019/03/12 06:00 [medline]
PST - ppublish
SO  - Cutis. 2018 Oct;102(4):283-286.